In this video, Motley Fool health-care bureau chief Brenton Flynn takes a look through some recent SEC filings where investors don't often look for information, to discover some of the less-reported information on some of the biggest names in the health-care investments sector today. He discusses Abbott Labs (NYSE: ABT) and its coming spinoff AbbVie, a new indication for Questcor (NASDAQ: QCOR), a savvy sell by Dendreon (NASDAQ: DNDN), general pessimism about the economic climate from Express Scripts (NASDAQ: ESRX), and some uncertainty from MAKO Surgical (NASDAQ:MAKO) in the wake of Hurricane Sandy.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/22/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.